Sage Therapeutics shares are trading lower after the Phase 2 KINETIC 2 study of SAGE-324 did not demonstrate a statistically significant dose-response relationship on the primary endpoint.
Portfolio Pulse from Benzinga Newsdesk
Sage Therapeutics shares are trading lower after the Phase 2 KINETIC 2 study of SAGE-324 did not demonstrate a statistically significant dose-response relationship on the primary endpoint.
July 24, 2024 | 10:34 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sage Therapeutics shares are trading lower due to the Phase 2 KINETIC 2 study of SAGE-324 not demonstrating a statistically significant dose-response relationship on the primary endpoint.
The failure to demonstrate a statistically significant dose-response relationship in the Phase 2 KINETIC 2 study of SAGE-324 is a negative development for Sage Therapeutics. This outcome likely reduces investor confidence in the potential success of SAGE-324, leading to a decline in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100